Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nusinersen efficacy data for 24‐month in type 2 and 3 spinal muscular atrophy
Marika Pane, Giorgia Coratti, Maria Carmela Pera, et al.
Annals of Clinical and Translational Neurology (2022) Vol. 9, Iss. 3, pp. 404-409
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Nucleic Acid Therapeutics: Successes, Milestones, and Upcoming Innovation
Jillian Belgrad, Hassan H. Fakih, Anastasia Khvorova
Nucleic Acid Therapeutics (2024) Vol. 34, Iss. 2, pp. 52-72
Closed Access | Times Cited: 36
Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry
Laurent Servais, John Day, Darryl C. De Vivo, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 2, pp. 425-442
Open Access | Times Cited: 26
Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience
Anna Łusakowska, Adrianna Wójcik, Anna Frączek, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 34
New therapies for spinal muscular atrophy: where we stand and what is next
Laura Antonaci, Maria Carmela Pera, Eugenio Mercuri
European Journal of Pediatrics (2023) Vol. 182, Iss. 7, pp. 2935-2942
Open Access | Times Cited: 27
An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies
Doris Giess, Judit Erdos, Claudia Wild
European Journal of Paediatric Neurology (2024) Vol. 51, pp. 84-92
Closed Access | Times Cited: 10
Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence
Helgi Thor Hjartarson, Kristofer Nathorst-Böös, Thomas Sejersen
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1865-1883
Open Access | Times Cited: 38
Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data
Andrej Belančić, Tea Strbad, Marta Kučan, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2839-2839
Open Access | Times Cited: 19
Disease Trajectories in the Revised Hammersmith Scale in a Cohort of Untreated Patients with Spinal Muscular Atrophy types 2 and 3
Amy Wolfe, Georgia Stimpson, Danielle Ramsey, et al.
Journal of Neuromuscular Diseases (2024) Vol. 11, Iss. 3, pp. 665-677
Open Access | Times Cited: 7
Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study
Astrid Pechmann, Max Behrens, Katharina Dörnbrack, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 28
Determining minimal clinically important differences in the Hammersmith Functional Motor Scale Expanded for untreated spinal muscular atrophy patients: An international study
Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 6
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3
Federica Trucco, Deborah Ridout, Harriet Weststrate, et al.
Neurology Clinical Practice (2024) Vol. 14, Iss. 3
Closed Access | Times Cited: 4
An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy
Yueyi Li, Hongyu Zeng, Yuhao Wei, et al.
Human Gene Therapy (2023) Vol. 34, Iss. 5-6, pp. 180-191
Closed Access | Times Cited: 10
Spinal Muscular Atrophy (SMA): Treatment strategies, challenges and future prospects
Nikunja Kishor Mishra, Amiyakanta Mishra
Deleted Journal (2025), pp. 100031-100031
Closed Access
Myostatin Levels in SMA Following Disease‐Modifying Treatments: A Multi‐Center Study
Fiorella Piemonte, Sara Petrillo, Anna Capasso, et al.
Annals of Clinical and Translational Neurology (2025)
Open Access
Effectiveness of Nusinersen in Adolescents and Adults with Spinal Muscular Atrophy: Systematic Review and Meta-analysis
Tim Hagenacker, Lorenzo Maggi, Giorgia Coratti, et al.
Neurology and Therapy (2024) Vol. 13, Iss. 5, pp. 1483-1504
Open Access | Times Cited: 3
Advances and Challenges in Gene Therapy for Neurodegenerative Diseases: A Systematic Review
Nerea García-González, Jaime Gonçalves-Sánchez, Ricardo Gómez‐Nieto, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 23, pp. 12485-12485
Open Access | Times Cited: 3
Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective
Lakshmi Balaji, Michelle A. Farrar, Arlene D’Silva, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 7, pp. 571-586
Closed Access | Times Cited: 8
Neonatal screening for spinal muscular atrophy: A pilot study in Brazil
Alice Brinckmann Oliveira Netto, Ana Carolina Brusius‐Facchin, Júlia F. Lemos, et al.
Genetics and Molecular Biology (2023) Vol. 46, Iss. 3 suppl 1
Open Access | Times Cited: 8
Examination of Upper Limb Function and the Relationship with Gross Motor Functional and Structural Parameters in Patients with Spinal Muscular Atrophy
Aleksandra Bieniaszewska, Magdalena Sobieska, Barbara Steinborn, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1005-1005
Open Access | Times Cited: 7
Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan
Yosuke Tachibana, Ryusuke Sato, Haruki Makioka, et al.
International Journal of Neuroscience (2023), pp. 1-13
Closed Access | Times Cited: 7
2-Year Change in Revised Hammersmith Scale Scores in a Large Cohort of Untreated Paediatric Type 2 and 3 SMA Participants
Georgia Stimpson, Danielle Ramsey, Amy Wolfe, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1920-1920
Open Access | Times Cited: 6
Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: findings from a three-year nationwide study in Korea
Jaeso Cho, Jiwon Lee, Ji-Hye Kim, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 6
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded
Giorgia Coratti, Francesca Bovis, Maria Carmela Pera, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 12
Open Access | Times Cited: 2
Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data Sources
Bora Youn, Crystal M. Proud, Nasha Wang, et al.
Advances in Therapy (2023) Vol. 40, Iss. 3, pp. 1129-1140
Open Access | Times Cited: 5
Newborn screening for spinal muscular atrophy - what have we learned?
Alzira Alves de Siqueira Carvalho, Cyril Tychon, Laurent Servais
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 11, pp. 1005-1012
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top